Cynata Therapeutics Concludes Patient Enrolment in Diabetic Foot Ulcer Wound Dressing Product Trial
Cynata Therapeutics (ASX:CYP) completed patient enrolment in its Phase 1 clinical trial of its topical wound dressing product candidate, CYP-006TK, in diabetic foot ulcers, according to a Monday filin
Cynata Therapeutics Receives EU Approval for CYP-001 Phase 2 Trial
Cynata Therapeutics (ASX:CYP) has secured regulatory and ethics approval from the European Union for the phase 2 clinical study of CYP-001 in high-risk acute graft versus host disease, according to a
Cynata Therapeutics' Breakthrough in Regenerative Medicine
Peter Milios: I am Peter Milios from the Finance News Network, and today I am talking with Cynata Therapeutics. Cynata is a clinical stage stem cell and regenerative medicine company. Their ASX code i
Cynata Therapeutics Doses First Patient in Phase Two Trial of Cellular Therapy; Shares Rise 5%
Cynata Therapeutics (ASX:CYP) dosed the first patient in its phase two trial investigating the use of the cellular therapy CYP-001 in patients with graft versus host disease. The randomized trial aims
Cynata Therapeutics Names Chief Business Officer; Shares Plunge 14%
Cynata Therapeutics (ASX:CYP) appointed Mathias Kroll as chief business officer, effective mid-April, the clinical-stage biotechnology company said Thursday. Kroll will join Cynata from QIMR Berghofer
Companies Like Cynata Therapeutics (ASX:CYP) Could Be Quite Risky
Cynata Therapeutics Expects Initial Results in Diabetic Foot Ulcer Topical Wound Dressing Trial in Q1 2024
Cynata Therapeutics (ASX:CYP) said it's expecting initial results in the Phase 1 clinical trial of its topical wound dressing product candidate CYP-006TK in diabetic foot ulcer in the first quarter of
Cynata Therapeutics Completes Recruitment for Phase Three Osteoarthritis Trial
Cynata Therapeutics (ASX:CYP) completed the recruitment of 321 participants for a phase three trial investigating the use of cell therapy CYP-004 to treat osteoarthritis, the stem cell and regenerativ
Cynata Therapeutics Secures Approval in Turkey for Phase 2 Trial of HR-aGvHD; Shares Jump 9%
Cynata Therapeutics (ASX:CYP) received regulatory and ethics approval to commence its phase II clinical trial of CYP-001 in patients with high-risk acute graft versus host disease (HR-aGvHD) at clinic
Cynata Therapeutics Receives AU$2.3 Million R&D Tax Rebate
Cynata Therapeutics (ASX:CYP) received a AU$2.3 million research and development tax incentive refund for the 2022/2023 fiscal year. The rebate enables further investment toward advancing the company'
Cynata Therapeutics Secures Clearance to Advance Phase Three Knee Pain Trial
Cynata Therapeutics (ASX:CYP) secured clearance from an independent data safety and monitoring board to advance a phase three trial investigating the use of the stem cell therapy CYP-004 in patients w
Cynata Therapeutics Opens Enrollment for Phase Two Cell Therapy Trial
Cynata Therapeutics (ASX:CYP) opened the enrollment phase for a phase two clinical trial investigating the use of the cell therapy CYP-001 in high-risk acute graft versus host disease patients. The ra
We're Not Worried About Cynata Therapeutics' (ASX:CYP) Cash Burn
No Data